Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) had its price objective lifted by stock analysts at Citigroup Inc. from $154.00 to $155.00 in a note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup Inc.’s price target would suggest a potential upside of 18.90% from the company’s previous close.
Other research analysts also recently issued reports about the company. Jefferies Group reiterated a “hold” rating on shares of Alexion Pharmaceuticals in a report on Sunday, May 29th. Piper Jaffray Cos. restated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, June 26th. Leerink Swann restated a “buy” rating and issued a $200.00 price target on shares of Alexion Pharmaceuticals in a research note on Friday, July 8th. Credit Suisse Group AG upgraded Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Saturday, July 9th. Finally, Robert W. Baird restated a “neutral” rating and issued a $145.00 price target on shares of Alexion Pharmaceuticals in a research note on Monday, June 13th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $182.85.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 130.36 on Tuesday. Alexion Pharmaceuticals has a 52-week low of $110.56 and a 52-week high of $193.45. The company has a market capitalization of $29.23 billion, a PE ratio of 327.54 and a beta of 1.08. The stock’s 50 day moving average price is $131.16 and its 200-day moving average price is $135.82.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.17 by $0.04. The firm had revenue of $753 million for the quarter, compared to the consensus estimate of $743.18 million. Alexion Pharmaceuticals had a return on equity of 10.02% and a net margin of 3.19%. The firm’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.44 earnings per share. On average, analysts expect that Alexion Pharmaceuticals will post $4.65 earnings per share for the current year.
In related news, Director Alvin S. Parven sold 15,000 shares of the business’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $136.53, for a total transaction of $2,047,950.00. Following the sale, the director now owns 6,373 shares in the company, valued at approximately $870,105.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO David Hallal sold 332 shares of the business’s stock in a transaction on Monday, August 8th. The stock was sold at an average price of $137.14, for a total value of $45,530.48. Following the sale, the chief executive officer now owns 189,266 shares in the company, valued at approximately $25,955,939.24. The disclosure for this sale can be found here. 4.41% of the stock is owned by insiders.
A number of large investors have recently modified their holdings of the company. Evercore Wealth Management LLC increased its position in shares of Alexion Pharmaceuticals by 5.0% in the second quarter. Evercore Wealth Management LLC now owns 1,735 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 83 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund bought a new position in shares of Alexion Pharmaceuticals during the second quarter valued at approximately $1,056,000. Kentucky Retirement Systems bought a new position in shares of Alexion Pharmaceuticals during the second quarter valued at approximately $2,224,000. Mason Street Advisors LLC bought a new position in shares of Alexion Pharmaceuticals during the second quarter valued at approximately $3,523,000. Finally, Cowen Group Inc. increased its position in shares of Alexion Pharmaceuticals by 36.4% in the second quarter. Cowen Group Inc. now owns 4,500 shares of the biopharmaceutical company’s stock valued at $525,000 after buying an additional 1,200 shares during the last quarter. Institutional investors and hedge funds own 96.34% of the company’s stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.